Acquired Company
Journey Medical Corporation acquired Qbrexza from Dermira, Inc. on May 14, 2021; upfront $12.5 million and up to $144.0 million in milestone payments.
Journey Medical Corp (DERM) is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for dermatological conditions that present significant unmet medical needs. The company's robust pipeline includes a range of specialized products designed to improve patient outcomes, backed by strategic partnerships and a strong focus on clinical research. With its deep industry expertise and commitment to innovation, Journey Medical is strategically positioned to leverage growth opportunities in the evolving healthcare landscape, making it an appealing investment for institutional investors interested in the dermatology market. Show more
Location: 9237 EAST VIA DE VENTURA BOULEVARD, SCOTTSDALE, AZ, UNITED STATES, 85258, Scottsdale, AZ, 85258, USA | Website: https://journeymedicalcorp.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE
Market Cap
278M
52 Wk Range
$4.33 - $9.55
Previous Close
$8.45
Open
$8.44
Volume
76,929
Day Range
$8.32 - $8.60
Enterprise Value
281.4M
Cash
24.95M
Avg Qtr Burn
-2.383M
Insider Ownership
24.34%
Institutional Own.
32.74%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Emrosi™ (Formerly DFD-29) Details Papulopustular rosacea | Approved Quarterly sales |
